Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis
Authors' conclusion
This post hoc analysis of patients with JIA indicated normal or higher than expected growth velocity during long-term treatment, with tofacitinib with catch-up growth during puberty and, overall, no concerning changes in biomarkers of GH signalling.
Study context
- Population
- Patients primarily with polyarticular-course JIA receiving long-term tofacitinib137 with biomarkers at 18 weeks
- Participants
- 225 participants
- Primary endpoint
- Growth: height velocities (cm/y) and height Z-scores (age- and sex-matched reference data)
Methodological detailsopen-label, long-term
- Open-label
- Long-term
Primary result
As reported in the abstract
Growth during tofacitinib treatment
- Height velocities appeared greater (patients ≤12 years) or as expected (patients >12 years) relative to age reference
- Height Z-scores largely stable during treatment
- Baseline height distribution similar to the general population
- Median [IQR] follow-up 3.6 [1.9-4.6] years
Further findings
Height Z-score in patients in puberty with baseline Z-score less than --1.0 (subgroup) · 24 months
- Increase in height Z-score
- P < 0.05
IGF-1, IGF binding protein 3 and osteocalcin · 18 weeks
- No impact in the overall population
- IGF-1 increased from baseline to 18 weeks in patients aged 6 to 12 years
Original publication
Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis. Ann Rheum Dis. Published 30 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →